German industrial conglomerate Siemens AG took another major step toward restructuring when it unveiled a plan on Nov. 4 that includes the divestiture of businesses with annual sales of $10.2 billion. Unaffected by the restructuring is the company’s
German industrial conglomerate Siemens AG took another major step toward restructuring when it unveiled a plan on Nov. 4 that includes the divestiture of businesses with annual sales of $10.2 billion. Unaffected by the restructuring is the companys Medical Engineering Group, which continues to post an encouraging turnaround, according to the company.
Siemens AG president and CEO Heinrich von Pierer has been restructuring the company for the past year, shedding underperforming business units. This months news represents the most radical move yet in his campaign to reshape Siemens, however.
The bulk of Von Pierers plans involve the companys Components group, which consists of operations in semiconductors, passive components and electron tubes, and electromechanical components. The semiconductors business will be spun off as an independent company, while Siemens is still examining its options for the passive components and electron tubes business. Siemens is also seeking a partner for the electromechanical components business. The businesses to be divested have annual sales of about $10.2 billion.
Siemens reported that operations in its Medical Engineering Group have improved significantly since the unit reported an operating loss last year. Medical Engineering reported annual sales of $4.5 billion, up 11% compared with sales from continuing operations last year. The groups operating profit before taxes was $100.3 million, compared with a loss of $102.1 million the year before.
Seven Takeaways from Meta-Analysis of PSMA Radiotracers for Prostate Cancer Imaging
December 1st 2023In a newly published meta-analysis of 24 studies, researchers noted that the PSMA PET radiotracer 18F PSMA-1007 may provide more benefit than 68Ga Ga-PSMA-11 for primary staging of patients with prostate cancer and detection of local lesion recurrence, but also has drawbacks with higher liver uptake and multiple reports of false positive bone lesions.
GE HealthCare Launches AI Mammography Platform with Key Applications from iCAD
November 30th 2023Offering an all-in-one platform of artificial intelligence (AI) applications, MyBreastAI Suite reportedly facilitates early breast cancer detection and enhances efficiency with breast imaging workflows.